SCHEMBL4766014

SCHEMBL4766014

O=C(CCc1ccccn1)Nc1cc(-c2cccnc2)nc(-c2ccccn2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 7/20 0.47
ADORA3 P0DMS8 5/20 0.47
ADORA2A P29274 5/20 0.47
CYP2A6 P11509 1/20 0.45
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
ADORA2B P29275 1/20 0.44
ALDH1A1 P00352 2/20 0.43
LMNA P02545 1/20 0.43
NPC1 O15118 1/20 0.42
TP53 P04637 1/20 0.42
PKM P14618 1/20 0.42
TSHR P16473 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
GBA1 P04062 1/20 0.41
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4773065 0.88 ADORA1 (0.43) ADORA1ADORA3ADORA2ACYP2A6ADORA2B
SCHEMBL4765953 0.85 LMNA (0.52) MAPK1HTTALDH1A1LMNANPC1
SCHEMBL4771758 0.85 ADORA1 (0.43) ADORA1ADORA3ADORA2ACYP2A6HTT
SCHEMBL4770635 0.83 CYP1A2 (0.52) ADORA1ADORA3ADORA2AMAPK1ALDH1A1
SCHEMBL4768829 0.83 KDM4E (0.44) ADORA1ADORA3ADORA2ACYP2A6ADORA2B
SCHEMBL2240945 0.83 GBA1 (0.54) CYP2A6ALDH1A1NPC1TP53PKM
SCHEMBL4769061 0.82 ADORA2A (0.43) ADORA1ADORA3ADORA2AHTTADORA2B
SCHEMBL4768684 0.82 ADORA2A (0.43) ADORA1ADORA3ADORA2ACYP2A6ADORA2B
SCHEMBL4775234 0.82 LMNA (0.49) MAPK1HTTALDH1A1LMNANPC1
SCHEMBL4769102 0.82 KMT2A (0.55) ADORA1ADORA3ADORA2AMAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1878733-A1 Pyrimidine derivatives as ALK-5 inhibitors Novartis AG (CH) 2008-01-16 EP disclosed